Handa Pharmaceuticals, Inc. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was TWD 566.26 million compared to TWD 40.96 million a year ago. Net income was TWD 494.03 million compared to net loss of TWD 86.38 million a year ago.

Basic earnings per share from continuing operations was TWD 3.79 compared to basic loss per share from continuing operations of TWD 0.71 a year ago. Diluted earnings per share from continuing operations was TWD 3.78 compared to diluted loss per share from continuing operations of TWD 0.71 a year ago.